2. Search Result
Search Result
Results for "

PD-L1-IN-2

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

6

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149830
    PD-L1-IN-2

    		PD-1/PD-L1 Cancer
    PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research .
    PD-L1-IN-2
  • HY-P9997
    Rosnilimab

    ANB030

    		 PD-1/PD-L1 Cancer
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
    Rosnilimab
  • HY-P99144
    Anti-Mouse PD-1 Antibody (RMP1-14)
    4 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG2a antibody inhibitor.
    Anti-Mouse PD-1 Antibody (RMP1-14)
  • HY-P99145
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
    2 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
  • HY-156150
    CYP51/PD-L1-IN-2

    		Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-2
  • HY-P99106
    Acrixolimab

    		PD-1/PD-L1 Cancer
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
    Acrixolimab
  • HY-162816
    PROTAC HPK1 Degrader-3

    		PROTACs MAP4K Cancer
    PROTAC PD-L1 degrader-2 (compound C3) is an orally effective PROTAC targeting HPK1 (DC50=21.26 nM). HPK1 is a negative regulator of T cell receptors, which can lead to T cell dysfunction after abnormal activation. PROTAC PD-L1 degrader-2 can inhibit SLP76 and NF-κB signaling pathways and inhibit MAPK signal transduction, and has anticancer activity and immune activation. PROTAC PD-L1 degrader-2 has a certain oral bioavailability and can be combined with PD-L1 antibody therapy to achieve a tumor growth inhibition rate of 65.58%. PROTAC PD-L1 degrader-2 is composed of E3 ligase ligand Thalidomide (HY-14658; blue part), PROTAC linker tert-Butyl 3-oxoazetidine-1-carboxylate (HY-40146; black part), and target protein ligand HPK1-IN-51 (HY-162842; red part); the activity control of the target protein ligand can be HPK1 ligand 1 (HY-162841) [1] .
    PROTAC HPK1 Degrader-3
  • HY-162841
    HPK1 ligand 1

    		Ligands for Target Protein for PROTAC Cancer
    HPK1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HPK1 ligand 1 can be used for synthesis PROTAC PD-L1 degrader-2 (HY-162816) .
    HPK1 ligand 1
  • HY-162842
    HPK1-IN-51

    		Ligands for Target Protein for PROTAC Cancer
    HPK1-IN-51 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HPK1-IN-51 can be used for synthesis PROTAC PD-L1 degrader-2 (HY-162816) .
    HPK1-IN-51
  • HY-162840
    Thalidomide-azetidin-3-one

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-azetidin-3-one is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-azetidin-3-one can be used to synthesize PROTAC PD-L1 degrader-2 (HY-162816) .
    Thalidomide-azetidin-3-one
  • HY-P99639
    Geptanolimab

    APL-501; CBT-501; GB-226

    		 PD-1/PD-L1 Cancer
    Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
    Geptanolimab
  • HY-101093
    CA-170
    1 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .
    CA-170
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    2 Publications Verification

    MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

    		 PD-1/PD-L1 Cancer
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
    Pembrolizumab (anti-PD-1)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: